Genetically engineered Glofish spark controversy
The nation’s first genetically engineered pet glows in the dark and has been lighting up cash registers in Michigan pet shops. But Glofish, created by splicing a sea anemone gene into a zebra fish, may not be available for long.
Counterfeiters have moved beyond bogus currency and fake designer handbags into the lucrative world of prescription drugs, setting off a technology race to foil copycats who profit on phony pharmaceuticals.
Biotech industry raises $16.4B in new funding in 2003
The biotechnology industry raised $16.4 billion in new financing and earned 37 FDA approvals in 2003, the Biotechnology Industry Organization in Washington, D.C., said Monday.
New work shows the promise, and pitfalls, of embryonic-stem-cell research
A Happy Pill for Some Biotechs
Analysts predict 2003’s rally will continue, with the winners changing to include a few blue-chip names and select up-and-comers.
Biotech: A Coming Boom — or Bust?
Two industry veterans lay out contrasting views about what the sector and its investors can expect over the next 12 months.
Biotech may be poised for “big year”
Biotechnology is poised for a boom year in 2004, wrapping up 2003 with a strong recovery and plenty of reason for optimism, in the forecast of G. Steven Burrill, chief executive officer of the San Francisco-based life sciences merchant bank, Burrill & Co.
Corporate lawyers haven’t had much to celebrate since the Internet bubble burst, but a recent stock market run on life sciences companies is breathing new buoyancy into some practices.
When Patents Persist
What if that patent you’re paying royalties on suddenly gets extended? Have you negotiated the best licensing deal possible?
Amgen’s Cannibalistic Ways
If you don’t think that Amgen is excited about its future, check out what the company is piling on its plate. The biotech giant will be earmarking half of next year’s revenue to launch a $5 billion share buyback.